Holyoake TL - Search Results

1

Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis.

Strathdee G, Holyoake TL, Sim A, Parker A, Oscier DG, Melo JV, Meyer S, Eden T, Dickinson AM, Mountford JC, Jorgensen HG, Soutar R, Brown R. Strathdee G, et al. Among authors: holyoake tl. Clin Cancer Res. 2007 Sep 1;13(17):5048-55. doi: 10.1158/1078-0432.CCR-07-0919. Clin Cancer Res. 2007. PMID: 17785556 Free article.

2

Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3.

Holyoake TL, Jiang X, Jorgensen HG, Graham S, Alcorn MJ, Laird C, Eaves AC, Eaves CJ. Holyoake TL, et al. Blood. 2001 Feb 1;97(3):720-8. doi: 10.1182/blood.v97.3.720. Blood. 2001. PMID: 11157490 Free article.

3

A comparison of normal and leukemic stem cell biology in Chronic Myeloid Leukemia.

Jørgensen HG, Holyoake TL. Jørgensen HG, et al. Among authors: holyoake tl. Hematol Oncol. 2001 Sep;19(3):89-106. doi: 10.1002/hon.667. Hematol Oncol. 2001. PMID: 11574931 Review.

4

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.

Graham SM, Jørgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, Holyoake TL. Graham SM, et al. Among authors: holyoake tl. Blood. 2002 Jan 1;99(1):319-25. doi: 10.1182/blood.v99.1.319. Blood. 2002. PMID: 11756187 Free article.

5

Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571.

Jørgensen HG, Elliott MA, Allan EK, Carr CE, Holyoake TL, Smith KD. Jørgensen HG, et al. Among authors: holyoake tl. Blood. 2002 Jan 15;99(2):713-5. doi: 10.1182/blood.v99.2.713. Blood. 2002. PMID: 11781261 Free article.

6

Is there a cloud in the silver lining for imatinib?

Paterson SC, Smith KD, Holyoake TL, Jørgensen HG. Paterson SC, et al. Among authors: holyoake tl. Br J Cancer. 2003 Apr 7;88(7):983-7. doi: 10.1038/sj.bjc.6600828. Br J Cancer. 2003. PMID: 12671692 Free PMC article. Review.

7

Fatal peripheral neuropathy following FLA chemotherapy.

Osborne WL, Holyoake TL, McQuaker IG, Parker AN. Osborne WL, et al. Among authors: holyoake tl. Clin Lab Haematol. 2004 Aug;26(4):295-6. doi: 10.1111/j.1365-2257.2004.00613.x. Clin Lab Haematol. 2004. PMID: 15279668

8

Punish the parent not the progeny.

Elrick LJ, Jorgensen HG, Mountford JC, Holyoake TL. Elrick LJ, et al. Among authors: holyoake tl. Blood. 2005 Mar 1;105(5):1862-6. doi: 10.1182/blood-2004-08-3373. Epub 2004 Nov 4. Blood. 2005. PMID: 15528314 Free article. Review.

9

Granulocyte--colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia.

Jørgensen HG, Copland M, Holyoake TL. Jørgensen HG, et al. Among authors: holyoake tl. Cancer. 2005 Jan 1;103(1):210-11. doi: 10.1002/cncr.20742. Cancer. 2005. PMID: 15540243 Free article. No abstract available.

10

Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro.

Jørgensen HG, Allan EK, Graham SM, Godden JL, Richmond L, Elliott MA, Mountford JC, Eaves CJ, Holyoake TL. Jørgensen HG, et al. Among authors: holyoake tl. Leukemia. 2005 Jul;19(7):1184-91. doi: 10.1038/sj.leu.2403785. Leukemia. 2005. PMID: 15889158

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

216 results

Search Page